University of British Columbia-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:University of British Columbia - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013631
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
University of British Columbia (UBC) is a research institute that offers educational services. The university provides undergraduate, graduate educational programs, and research programs through its schools and faculties. It provides cultural, recreational and social activities for its students. UBC offers educational services through programs such a professional programs, English language pathways, joint academic programs, exchange programs, co-operative education, innovative learning initiatives and distance education programs. The university serves adult education needs of lifelong learners by providing educational programs in UBC’s Point Grey campus. It operates through peer institutions, government, non-profit and other industries for its research activities. The university operates in two campuses namely, Vancouver Campus and Okanagan Campus. UBC is headquartered in Vancouver, British Columbia, Canada

University of British Columbia – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
University of British Columbia, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
University of British Columbia, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
University of British Columbia, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
University of British Columbia, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
University of British Columbia, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
University of British Columbia, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
AXIM Biotech Enters into Agreement with University of British Columbia 12
Replicel Life Sciences Enters into Agreement with University of British Columbia 13
Ritter Pharma Enters into Agreement with University of British Columbia 14
TxCell Enters into Research Agreement with University of British Columbia 15
ProtoKinetix Enters into Research Agreement with University of British Columbia 16
Sirona Biochem Enters into Research Agreement with University of British Columbia 17
Qu Biologics Enters into Research Agreement with University of British Columbia 18
InMed Pharma Enters into Agreement with University of British Columbia 19
University of British Columbia Enters Into Agreement With Sichuan BoXin LaiTe Biotechnology And Heracles International Investment 20
Cangene Enters Into Research Agreement With University Of British Columbia 21
AlCana Extends Co-Development Agreement With UBC And Alnylam 22
CDRD Enters Into Co-Development Agreement With NGDI-UBC 23
Licensing Agreements 24
Roche Enters into Licensing Agreement with University of British Columbia and Vancouver Coastal Health Research Institute 24
BirchBioMed Enters into Licensing Agreement with University of British Columbia 25
Cyon Therapeutics Enters into Licensing Agreement with University of British Columbia 26
Cangene Enters Into Licensing Agreement With University of British Columbia 27
Advanced Inhalation Therapies Enters into Licensing Agreement with University of British Columbia 28
University of British Columbia – Key Competitors 29
University of British Columbia – Key Employees 30
University of British Columbia – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 33
Government and Public Interest 33
Oct 03, 2017: Avon Foundation for Women (Canada) funds new breast cancer recovery trial in partnership with two Canadian universities 33
Sep 12, 2017: Alzheimer Society Research Program provides $3.4 million boost to dementia research 34
Jul 28, 2017: UBC researchers working to engineer ‘tunable’ insulin production 35
Nov 16, 2016: Marijuana could Help Treat Drug Addiction, Mental Health 36
Jul 15, 2016: Cell research could help with heart tissue transplants 37
Jun 16, 2016: BC Children’s Hospital researchers discover an early warning sign of transplant rejection 38
Jun 01, 2016: UBC-Vancouver Coastal Health scientists find genetic cause of multiple sclerosis 39
May 02, 2016: Childhood asthma research receives $2 million to investigate genetic and environmental factors 41
Apr 06, 2016: Results of World’s First Study on New Treatment for Heroin Addiction 42
Product News 43
Oct 26, 2017: Vanderbilt leads international effort to develop universal flu vaccine 43
Sep 28, 2016: Antibiotics developed in 1960s show promise for TB therapy 44
Sep 07, 2016: UBC and Tilray Launch Canada’s First Clinical Trial to Study Medical Cannabis and PTSD 45
Clinical Trials 46
Oct 13, 2016: OncoGenex Announces Results from the Phase 3 ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer 46
Oct 10, 2016: ESMO 2016: Custirsen Shows no Survival Benefits in Metastatic Prostate Cancer 47
Aug 16, 2016: OncoGenex Announced Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer 48
Other Significant Developments 49
Oct 26, 2017: The Human Vaccines Project Launches New Initiative To Accelerate Development Of Universally Effective Influenza Vaccines 49
Oct 17, 2017: Scientific Update for Diabetes, Kidney Ischemia, Liver Perfusion, Retinal Cell Replacement, Monoclonal Antibody Production and Immune Cell Cryopreservation Recovery 50
Jun 24, 2016: Genome British Columbia Investing in Companies and Jobs Through e@UBC 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
University of British Columbia, Pharmaceuticals & Healthcare, Key Facts 2
University of British Columbia, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
University of British Columbia, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
University of British Columbia, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
University of British Columbia, Deals By Therapy Area, 2011 to YTD 2017 9
University of British Columbia, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
AXIM Biotech Enters into Agreement with University of British Columbia 12
Replicel Life Sciences Enters into Agreement with University of British Columbia 13
Ritter Pharma Enters into Agreement with University of British Columbia 14
TxCell Enters into Research Agreement with University of British Columbia 15
ProtoKinetix Enters into Research Agreement with University of British Columbia 16
Sirona Biochem Enters into Research Agreement with University of British Columbia 17
Qu Biologics Enters into Research Agreement with University of British Columbia 18
InMed Pharma Enters into Agreement with University of British Columbia 19
University of British Columbia Enters Into Agreement With Sichuan BoXin LaiTe Biotechnology And Heracles International Investment 20
Cangene Enters Into Research Agreement With University Of British Columbia 21
AlCana Extends Co-Development Agreement With UBC And Alnylam 22
CDRD Enters Into Co-Development Agreement With NGDI-UBC 23
Roche Enters into Licensing Agreement with University of British Columbia and Vancouver Coastal Health Research Institute 24
BirchBioMed Enters into Licensing Agreement with University of British Columbia 25
Cyon Therapeutics Enters into Licensing Agreement with University of British Columbia 26
Cangene Enters Into Licensing Agreement With University of British Columbia 27
Advanced Inhalation Therapies Enters into Licensing Agreement with University of British Columbia 28
University of British Columbia, Key Competitors 29
University of British Columbia, Key Employees 30
University of British Columbia, Other Locations 31
University of British Columbia, Subsidiaries 31

★海外企業調査レポート[University of British Columbia-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ivenix Inc:医療機器:M&Aディール及び事業提携情報
    Summary Ivenix Inc (Ivenix), formerly Fluidnet Corp is a medical technology company that offers infusion therapy solutions. The company offers products such as IV smart pumps and intravenous drug infusion pump systems. Its IV smart pumps eliminate air from fluid bag and IV lines to reduce number of …
  • Mizuno Corporation (8022):企業の財務・戦略的SWOT分析
    Mizuno Corporation (8022) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Sequa Petroleum NV:石油・ガス:M&Aディール及び事業提携情報
    Summary Sequa Petroleum NV (Sequa Petroleum) is an oil and gas company that develops, acquires, monetises, produces and finances oil and natural gas assets. The company holds assets in Kazakhstan, North Western Europe and Sub Saharan Africa. Its Kazakhstan exploration site is located in Aksai block …
  • Ingles Markets Inc:企業の戦略・SWOT・財務分析
    Ingles Markets Inc - Strategy, SWOT and Corporate Finance Report Summary Ingles Markets Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • GE Global Research-医療機器分野:企業M&A・提携分析
    Summary GE Global Research (GE Global), a subsidiary of General Electric Company is a research and development company that develops technologies for various industry sectors. The company offers diverse technologies which are used in electronics, chemistry, biosciences, computing, metallurgy, fluid …
  • Novatek (NVTK):石油・ガス:M&Aディール及び事業提携情報
    Summary Novatek (Novatek) is an independent oil and gas company. The company explores, produces, processes, and markets natural gas and liquid hydrocarbons. Its licensed producing fields include, Yurkharovskoye, East-Tarkosalinskoye, Khancheyskoye, Olimpiyskiy, Yumantilskiy, Samburgskiy, North-Ureng …
  • Georox Resources Inc (GXR):石油・ガス:M&Aディール及び事業提携情報
    Summary Georox Resources Inc (Georox Resources), formerly Oromonte Resources Inc is an oil and gas company that acquires, develops and explores petroleum and natural gas properties in Western Canada. The company's projects include Silverdale property, GP Channel project, Sparky Non Channel project, …
  • Euronet Worldwide Inc (EEFT):企業の財務・戦略的SWOT分析
    Euronet Worldwide Inc (EEFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Zen Technologies Limited:企業の戦略・SWOT・財務分析
    Zen Technologies Limited - Strategy, SWOT and Corporate Finance Report Summary Zen Technologies Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Electricity Generating Public Co Ltd:発電所・企業SWOT分析
    Electricity Generating Public Co Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Mizuho Financial Group Inc:企業の戦略・SWOT・財務分析
    Mizuho Financial Group Inc - Strategy, SWOT and Corporate Finance Report Summary Mizuho Financial Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Wallenstam AB (WALL B):企業の財務・戦略的SWOT分析
    Summary Wallenstam AB (Wallenstam) is a construction company that offers building and property management solutions. The company's services include commercial and residential properties development, housing programs, property investment and management, urban development, property ownership services, …
  • Faron Pharmaceuticals Oy (FARN)-医療機器分野:企業M&A・提携分析
    Summary Faron Pharmaceuticals Oy (Faron Pharma) is a drug company that carries out clinical stage drug discovery and development. The company's product portfolio includes traumakine; clevegen; farbetic, an AOC3 inhibitor and D-ARDS, a diagnostic tool. Its traumakine clinical programme manages the tr …
  • Bachmann electronic GmbH:企業の戦略的SWOT分析
    Bachmann electronic GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • MetaStat Inc (MTST):医療機器:M&Aディール及び事業提携情報
    Summary MetaStat Inc (MetaStat) is a biotechnology company that discovers and develops personalized diagnostic and therapeutic treatment solutions for cancer patients. The company develops therapeutic product candidates based on novel approach that offers intracellular Mena protein isoforms drugable …
  • Lenovo Group Limited:企業の戦略・SWOT・財務分析
    Lenovo Group Limited - Strategy, SWOT and Corporate Finance Report Summary Lenovo Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Shanghai Kehua Bio-engineering Co Ltd (002022):製薬・医療:M&Aディール及び事業提携情報
    Summary Shanghai Kehua Bio-engineering Co Ltd (KHB) is a medical device company that develops, manufactures and markets in vitro diagnostic devices and related products. The company’s major product portfolio includes enzyme immunoassay kits, clinical chemistry reagents, PCR kits, rapid test kits, ch …
  • CryoPort Inc (CYRX):企業の財務・戦略的SWOT分析
    CryoPort Inc (CYRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Hutchinson SA:企業の戦略的SWOT分析
    Hutchinson SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Vericel Corp (VCEL)-医療機器分野:企業M&A・提携分析
    Summary Vericel Corp (Vericel) formerly Aastrom Biosciences, Inc. is a medical device company that develops patient-specific expanded cellular therapies to repair and regenerate damaged tissue for the treatment of severe, chronic ischemic cardiovascular diseases. It markets two autologous cell thera …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆